Table 3.

Influence of NR3C1 (GR) expression on BCa patient survival.

Type	Comparison	Increased survival	P-value	HR	Reference
ESR1+ untreated	NR3C1 low vs high	NR3C1-high	0.03	0.6	Pan et al. 2011
ESR1+ tamoxifen	NR3C1 low vs high	NR3C1-high	7.70E−08	0.25	Pan et al. 2011
ESR1− untreated	NR3C1 low vs high	NR3C1-low	0.001	2.23	Pan et al. 2011
ESR1− chemotherapy	NR3C1 low vs high	NR3C1-low	5.80E−07	6.83	Pan et al. 2011
ESR1+	NR3C1 low vs high	NR3C1-high	7.80E−14	0.35	West et al. 2016
ESR1+ PGR-high	NR3C1 low vs high	NR3C1-high	2.30E−07	0.35	West et al. 2016
ESR1+ PGR-low	NR3C1 low vs high	NR3C1-high	4.10E−06	0.4	West et al. 2016
TNBC basal-like 1	NR3C1 low vs high	NR3C1-low	0.013	1.87	West et al. 2018
TNBC basal-like 2	NR3C1 low vs high	No difference	0.64	NA	West et al. 2018
TNBC mesenchymal	NR3C1 low vs high	NR3C1-low	0.04	1.65	West et al. 2018
TNBC luminal AR	NR3C1 low vs high	NR3C1-low	0.015	1.68	West et al. 2018

AR, androgen receptor; ESR1, estrogen receptor α; HR, hazard ratio; NA, not applicable or indicated; NR3C1, glucocorticoid receptor; PGR, progesterone receptor; TNBC, triple negative breast cancer.